160 related articles for article (PubMed ID: 17318473)
1. [Capillary electrophoresis coupled to mass spectrometry for proteome analysis. An innovative diagnostic method for prostate and bladder cancer].
Wittke S; Schiffer E; Bauer HW
Urologe A; 2007 Jul; 46(7):733-9. PubMed ID: 17318473
[TBL] [Abstract][Full Text] [Related]
2. Predictive modeling in proteomics-based disease detection.
Pham TD
Annu Int Conf IEEE Eng Med Biol Soc; 2007; 2007():3308-11. PubMed ID: 18002703
[TBL] [Abstract][Full Text] [Related]
3. Prediction of muscle-invasive bladder cancer using urinary proteomics.
Schiffer E; Vlahou A; Petrolekas A; Stravodimos K; Tauber R; Geschwend JE; Neuhaus J; Stolzenburg JU; Conaway MR; Mischak H; Theodorescu D
Clin Cancer Res; 2009 Aug; 15(15):4935-43. PubMed ID: 19602546
[TBL] [Abstract][Full Text] [Related]
4. The use of Raman spectroscopy to provide an estimation of the gross biochemistry associated with urological pathologies.
Stone N; Hart Prieto MC; Crow P; Uff J; Ritchie AW
Anal Bioanal Chem; 2007 Mar; 387(5):1657-68. PubMed ID: 17123068
[TBL] [Abstract][Full Text] [Related]
5. Differential proteomic analysis of nuclear matrix in muscle-invasive bladder cancer: potential to improve diagnosis and prognosis.
Barboro P; Rubagotti A; Orecchia P; Spina B; Truini M; Repaci E; Carmignani G; Romagnoli A; Introini C; Boccardo F; Carnemolla B; Balbi C
Cell Oncol; 2008; 30(1):13-26. PubMed ID: 18219107
[TBL] [Abstract][Full Text] [Related]
6. Proteomic studies in urological malignancies.
Ferguson RE; Selby PJ; Banks RE
Contrib Nephrol; 2004; 141():257-79. PubMed ID: 14650238
[No Abstract] [Full Text] [Related]
7. Urinary proteome analysis for prostate cancer diagnosis: cost-effective application in routine clinical practice in Germany.
Schiffer E; Bick C; Grizelj B; Pietzker S; Schöfer W
Int J Urol; 2012 Feb; 19(2):118-25. PubMed ID: 22103570
[TBL] [Abstract][Full Text] [Related]
8. Multi-dimensional capillary electrophoresis and chromatography for proteomic analysis.
Gao M; Zhang X
Methods Mol Biol; 2008; 384():783-801. PubMed ID: 18392595
[TBL] [Abstract][Full Text] [Related]
9. Proteomic approaches to biomarker discovery in prostate and bladder cancers.
Adam BL; Vlahou A; Semmes OJ; Wright GL
Proteomics; 2001 Oct; 1(10):1264-70. PubMed ID: 11721637
[TBL] [Abstract][Full Text] [Related]
10. Proteome-based diagnostics and prognosis of bladder transitional cell carcinoma.
Wu TF; Ku WL; Tsay YG
Expert Rev Proteomics; 2007 Oct; 4(5):639-47. PubMed ID: 17941819
[TBL] [Abstract][Full Text] [Related]
11. Capillary electrophoresis-mass spectrometry for targeted and untargeted analysis of the sub-5 kDa urine metabolome of patients with prostate or bladder cancer: A feasibility study.
MacLennan MS; Kok MGM; Soliman L; So A; Hurtado-Coll A; Chen DDY
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Feb; 1074-1075():79-85. PubMed ID: 29334632
[TBL] [Abstract][Full Text] [Related]
12. Extracellular Vesicle Proteome in Prostate Cancer: A Comparative Analysis of Mass Spectrometry Studies.
Bernardino RMM; Leão R; Henrique R; Pinheiro LC; Kumar P; Suravajhala P; Beck HC; Carvalho AS; Matthiesen R
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948404
[TBL] [Abstract][Full Text] [Related]
13. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis.
Theodorescu D; Wittke S; Ross MM; Walden M; Conaway M; Just I; Mischak H; Frierson HF
Lancet Oncol; 2006 Mar; 7(3):230-40. PubMed ID: 16510332
[TBL] [Abstract][Full Text] [Related]
14. [Identification of AGR2 protein, a novel potential cancer marker, using proteomics technologies].
Kovalev LI; Shishkin SS; Khasigov PZ; Dzeranov NK; Kazachenko AV; Toropygin IIu; Mamykina SV
Prikl Biokhim Mikrobiol; 2006; 42(4):480-4. PubMed ID: 17022460
[TBL] [Abstract][Full Text] [Related]
15. SELDI proteinchip MS: a platform for biomarker discovery and cancer diagnosis.
Wright GL
Expert Rev Mol Diagn; 2002 Nov; 2(6):549-63. PubMed ID: 12465452
[TBL] [Abstract][Full Text] [Related]
16. Quantitative Proteomic Analysis Identifies AHNAK (Neuroblast Differentiation-associated Protein AHNAK) as a Novel Candidate Biomarker for Bladder Urothelial Carcinoma Diagnosis by Liquid-based Cytology.
Lee H; Kim K; Woo J; Park J; Kim H; Lee KE; Kim H; Kim Y; Moon KC; Kim JY; Park IA; Shim BB; Moon JH; Han D; Ryu HS
Mol Cell Proteomics; 2018 Sep; 17(9):1788-1802. PubMed ID: 29950347
[TBL] [Abstract][Full Text] [Related]
17. MALDI mass spectrometry in prostate cancer biomarker discovery.
Flatley B; Malone P; Cramer R
Biochim Biophys Acta; 2014 May; 1844(5):940-9. PubMed ID: 23831156
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in capillary electrophoresis coupled to mass spectrometry for clinical proteomic applications.
Stalmach A; Albalat A; Mullen W; Mischak H
Electrophoresis; 2013 Jun; 34(11):1452-64. PubMed ID: 23512263
[TBL] [Abstract][Full Text] [Related]
19. Clinical applications of capillary electrophoresis coupled to mass spectrometry in biomarker discovery: Focus on Bladder Cancer.
Latosinska A; Frantzi M; Vlahou A; Mischak H
Proteomics Clin Appl; 2013 Dec; 7(11-12):779-93. PubMed ID: 23970371
[TBL] [Abstract][Full Text] [Related]
20. Proteomic analysis of HBV-associated HCC: insights on mechanisms of disease onset and biomarker discovery.
Niu D; Feng H; Chen WN
J Proteomics; 2010 May; 73(7):1283-90. PubMed ID: 20188222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
